Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

Similar articles for PubMed (Select 11586210)

1.

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.

Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M.

J Urol. 2001 Nov;166(5):1724-8.

PMID:
11586210
2.

Skeletal fractures negatively correlate with overall survival in men with prostate cancer.

Oefelein MG, Ricchiuti V, Conrad W, Resnick MI.

J Urol. 2002 Sep;168(3):1005-7.

PMID:
12187209
3.

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.

Oefelein MG, Ricchiuti VS, Conrad PW, Goldman H, Bodner D, Resnick MI, Seftel A.

Urology. 2002 Jul;60(1):120-4.

PMID:
12100936
4.

Fracture risk in Danish men with prostate cancer: a nationwide register study.

Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K.

BJU Int. 2007 Oct;100(4):749-54.

PMID:
17822455
5.

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.

Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.

Can J Urol. 2007 Jun;14(3):3551-9.

PMID:
17594745
6.

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL.

J Clin Oncol. 2005 Nov 1;23(31):7897-903.

7.

Fracture risk in patients with prostate cancer on androgen deprivation therapy.

López AM, Pena MA, Hernández R, Val F, Martín B, Riancho JA.

Osteoporos Int. 2005 Jun;16(6):707-11. Epub 2005 Feb 16.

PMID:
15714259
8.

Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.

Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.

J Urol. 2007 Oct;178(4 Pt 1):1423-8. Epub 2007 Aug 16.

PMID:
17706711
9.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
10.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1.

PMID:
21807761
11.

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.

J Urol. 2009 Nov;182(5):2257-64. doi: 10.1016/j.juro.2009.07.046. Epub 2009 Sep 16.

PMID:
19758618
12.
13.

Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.

Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C.

J Urol. 2004 Aug;172(2):529-32.

PMID:
15247721
14.

Epidemiology of male osteoporosis and prostate cancer.

Gilbert SM, McKiernan JM.

Curr Opin Urol. 2005 Jan;15(1):23-7. Review.

PMID:
15586025
15.
16.

Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.

Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L.

J Urol. 2010 Sep;184(3):918-23. doi: 10.1016/j.juro.2010.04.068.

PMID:
20643458
17.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14. Epub 2006 Nov 28.

PMID:
17132807
18.
19.
20.

Management of bone loss in men with prostate cancer.

Higano CS.

J Urol. 2003 Dec;170(6 Pt 2):S59-63; discussion S64. Review.

PMID:
14610412
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk